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V35Gy, V30Gy, V25Gy and V20Gy were recorded and 
compared with standard statistical analysis. 
 
 
Results:  
 
 
Each defined contour allowed different constraint compliance 
for the oral cavity and made easier or more difficult to 
achieve the prescribed dose to the PTV. Results obtained for 
anterior OC showed the lowest Dmean and Dmax in this OAR. 
Anterior OC does not receive more than 30-35 Gy, however 
inner and extended OC receive 45-50 Gy (Fig. 1). These 
results allowed to apply a tighter constraint, decreasing the 
expected mucosa oral toxicity, and to achieve the prescribed 
doses to the PTV. Results for extended OC forced to apply a 
more relaxed constraint for the OAR to achieve the 
prescribed dose. Inner OC showed worse results compared 
with extended OC due probably to the differences of volume. 
As conclusion, different structures included in the oral cavity 
as OAR (different OC contours) imply different dose 
constraints and outcomes. 
Conclusions: It is necessary to define a consensus to unify 
the structures that should be included in the oral cavity as 
OAR in head-and-neck cancer patients treated with IMRT 
techniques. Differences among physicists´ criteria influence 
on OARs volume and furthermore, have an impact on 
constraint compliance for the oral cavity as OAR.  
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Purpose/Objective: The primary dose-limiting acute toxicity 
in irradiation of malignant lung tumors is acute esophagitis 
(AE). The aim of this study is to investigate dosimetric and 
clinical predictors for AE grade ≥ 2 in patients treated with 
accelerated radiotherapy for non-small-cell lung cancer 
(NSCLC). 
Materials and Methods: 66 patients with locally advanced 
NSCLC were included in the present study: 4 stage II, 44 stage 
IIIA and 18 stage IIIB. All patients received Platinum based 
induction chemotherapy followed by dose differentiated 
accelerated radiotherapy (DART - bid). Depending on size 
(mean of three perpendicular diameters) tumors were binned 
in four groups: < 2.5 cm 73.8 Gy, 2.5 – 4.5 cm 79.2 Gy, 4.5 – 6 
cm 84,6 Gy, > 6 cm 90 Gy. Patients were treated in 3D target 
splitting technique. In order to estimate the normal tissue 
complication probability (NTCP) two Lyman models and the 
cutoff-logistic regression model were fitted to the data. AE ≥ 
grade 2 was the statistical endpoint. Toxicity was 
documented prospectively according to RTOG. 
Results: With a median follow up of 686 days (range 84 – 
2921 days), the actuarial local control rates were 72.6% and 
59.4% at 2 and 3 years, regional control was 91%. The median 
overall survival was 25 months. 23/66 patients (35%) 
experienced AE ≥ grade 2. The Lyman-MED model (D50 = 32.8 
Gy, m = 0.48, n = 1) and the cutoff dose model (VDc = 38 Gy) 
provide the most efficient fit to the current dataset. On 
multivariate analysis V38 was the most significant predictor 
of AE ≥ grade 2 (HR = 1.05, CI 1.01 – 1.09, p = 0.009). 
Conclusions: The rate of AE ≥ grade 2 is slightly lower than 
with concomitant radio-chemotherapy, which is regarded as 
state-of-art treatment for locally advanced NSCLC. In the 
current patient cohort the most significant predictor of AE 
was found to be V38 (volume of the esophagus that receives 
38 Gy, CI 28.2 – 57.3).  
   
 
 
 
